- A recent study suggests a connection between severe COVID-19 requiring hospitalization and deficits in cognitive function that persist 6–10 months after illness onset.
- The cognitive deficits in COVID-19 survivors were of a similar magnitude to the decline in cognitive function that normally occurs in individuals between the ages of 50 to 70 years.
- The gradual recovery, if at all, of these persistent cognitive deficits highlights the importance of understanding the underlying mechanisms and developing treatment strategies.
- Mild COVID-19 cases may report lingering cognitive symptoms, but the study authors report that the incidence is higher in severe cases, with
33 % -76%having cognitive symptoms 3–6 months after hospitalization.
A recent study appearing in the journaleClinical Medicinesuggests that severe COVID-19 may be associated with persistent cognitive deficits, equivalent to a decline of 10 IQ points. In this study, severe COVID-19 was defined as COVID-19 that required hospitalization and critical care.
These cognitive deficits persisted until at least 6 months after contracting the SARS-CoV-2 infection, with a gradual improvement, if any, in these cognitive symptoms. These results underscore the importance of longer-term support for patients who have recovered from severe COVID-19.
According to official data from 2020, which is the same year that this study drew its adults data from, about 4 in 10 over the age of 18 are at risk of developing severe COVID-19 in the United States.
Although persistent cognitive symptoms are also observed in individuals with mild COVID-19, such deficits in cognitive function are more prevalent in individuals with severe COVID-19. Previous studies suggest that
However, further research is needed to understand the specific aspects of cognitive function that are affected after severe COVID-19 and the factors that predict these cognitive symptoms.
Previous studies characterizing persistent cognitive symptoms in COVID-19 patients have relied on self-reports, which are susceptible to bias. Other studies have used pen-and-paper neuropsychological tests to assess cognitive function.
However, these tests do not possess the sensitivity to detect small changes in cognitive function or distinguish the various domains or aspects of cognitive function impacted by a SARS-CoV-2 infection.
To address these concerns, the authors of the present study used computerized cognitive tests to objectively characterize specific domains of cognitive function impacted after severe acute COVID-19. These computerized tests also allow the researchers to assess the magnitude of these cognitive deficits.
Individuals with COVID-19 also experience persistent mental health symptoms such as anxiety, depression, fatigue, and post-traumatic stress disorder (PTSD), which could contribute to the deficits in cognitive function.
Another objective of the present study was to determine whether these mental health symptoms mediate the persistent cognitive deficits in COVID-19 patients.